Format

Send to

Choose Destination
Jpn J Clin Oncol. 2009 Mar;39(3):183-5. doi: 10.1093/jjco/hyn146. Epub 2009 Jan 24.

Metastatic adrenocortical carcinoma treated with sunitinib: a case report.

Author information

1
Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeongi-do, Republic of Korea.

Abstract

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

PMID:
19168875
DOI:
10.1093/jjco/hyn146
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center